KALA BIO (LSE:0JQ2) - Stock Price, News & Analysis

0JQ2 Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. More details

0JQ2 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 20.8% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 11.3% per year for the next 3 years

Shareholders have been substantially diluted in the past year

+ 2 more risks

KALA BIO, Inc. Competitors

OptiBiotix Health

AIM:OPTI

UK£12.2m

Hemogenyx Pharmaceuticals

LSE:HEMO

UK£16.1m

LungLife AI

AIM:LLAI

UK£2.8m

e-therapeutics

AIM:ETX

UK£52.6m

Price History & Performance

Summary of all time highs, changes and price drops for KALA BIO
Historical stock prices
Current Share Price	US$6.55
52 Week High	US$9.00
52 Week Low	US$4.47
Beta	-2.14
11 Month Change	13.90%
3 Month Change	9.90%
1 Year Change	5.65%
33 Year Change	-92.92%
5 Year Change	n/a
Change since IPO	-99.13%

Recent updates

Shareholder Returns

	0JQ2	GB Biotechs	GB Market
7D	-3.7%	-5.2%	0.8%
1Y	5.6%	-20.1%	6.6%

Return vs Industry: 0JQ2 exceeded the UK Biotechs industry which returned -20.1% over the past year.

Return vs Market: 0JQ2 matched the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0JQ2's price volatile compared to industry and market?
0JQ2 volatility
0JQ2 Average Weekly Movement	10.7%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0JQ2's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JQ2's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2009	43	Mark Iwicki	www.kalarx.com

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.

KALA BIO, Inc. Fundamentals Summary

How do KALA BIO's earnings and revenue compare to its market cap?
0JQ2 fundamental statistics
Market cap	US$30.18m
Earnings (TTM)	-US$38.96m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Is 0JQ2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JQ2 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$38.96m
Earnings	-US$38.96m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-8.46
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	253.8%

How did 0JQ2 perform over the long term?

See historical performance and comparison

0JQ2 Stock Overview

Rewards

Risk Analysis

KALA BIO, Inc. Competitors

AIM:OPTI

UK£12.2m

LSE:HEMO

UK£16.1m

AIM:LLAI

UK£2.8m

AIM:ETX

UK£52.6m

Price History & Performance

Recent News & Updates

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

Recent updates

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Insufficient new directors

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

New 90-day low: US$6.86

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Revenue misses expectations

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Shareholder Returns

Price Volatility

About the Company

KALA BIO, Inc. Fundamentals Summary

0.0x

-0.8x

Earnings & Revenue